Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Imatinib does not substantially modify the glycemic profile in patients with chronic myeloid leukaemia.

Mariani S, Tornaghi L, Sassone M, Basciani S, Buzzetti R, Gambacorti-Passerini C, Spera G, Gnessi L.

Leuk Res. 2010 Jan;34(1):e5-7. doi: 10.1016/j.leukres.2009.08.003. Epub 2009 Aug 29. No abstract available.

PMID:
19717189
2.

Modifications of fasting glucose values as first sign of resistance in chronic myeloid leukemia chronic phase patients during imatinib treatment.

Breccia M, Muscaritoli M, Cannella L, Loglisci G, Santopietro M, Alimena G.

Leuk Res. 2010 May;34(5):e122-4. doi: 10.1016/j.leukres.2009.11.021. Epub 2009 Dec 16. No abstract available.

PMID:
20018374
3.

[No influence of imatinib on type 2 diabetes].

Chodorowski Z, Sein Anand J, Hellmann A, Prejzner W.

Przegl Lek. 2007;64(4-5):370-1. Polish.

PMID:
17724918
4.

Imatinib and regression of type 2 diabetes.

Veneri D, Franchini M, Bonora E.

N Engl J Med. 2005 Mar 10;352(10):1049-50. No abstract available.

5.

Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment.

Breccia M, Muscaritoli M, Aversa Z, Mandelli F, Alimena G.

J Clin Oncol. 2004 Nov 15;22(22):4653-5. No abstract available.

6.

Are there new clinical parameters useful to predict response in chronic myeloid leukemia in the imatinib era?

Breccia M, Alimena G.

Leuk Res. 2009 Nov;33(11):1450-1. doi: 10.1016/j.leukres.2009.06.022. Epub 2009 Jul 16. No abstract available.

PMID:
19615745
7.

Reduction of glycosylated hemoglobin with stable insulin levels in a diabetic patient with chronic myeloid leukemia responsive to imatinib.

Breccia M, Muscaritoli M, Alimena G.

Haematologica. 2005 Nov;90 Suppl:ECR21. No abstract available.

8.

Diabetes research. Researchers puzzle over possible effect of Gleevec.

Couzin J.

Science. 2005 Mar 18;307(5716):1711. No abstract available.

PMID:
15774738
9.

Occurrences of opportunistic infections in chronic myelogenous leukemia patients treated with imatinib mesylate.

Anthony N, Shanks J, Terebelo H.

Leuk Res. 2010 Sep;34(9):1250-1. doi: 10.1016/j.leukres.2010.05.019. Epub 2010 Jun 19. No abstract available.

PMID:
20646761
10.

Antituberculosis therapy and imatinib for chronic myeloid leukemia.

Sorà F, De Matteis S, Di Mario A, Maiuro G, Laurenti L, Chiusolo P, Ardito F, Leone G, Sica S.

Clin Infect Dis. 2006 Nov 1;43(9):1224. No abstract available.

11.

Revised advice on use of imatinib for chronic myeloid leukaemia.

Campbell K.

Nurs Times. 2003 Oct 14-20;99(41):20-1.

PMID:
14603651
12.

STI-571 (Gleevec) in the treatment of chronic myeloid leukaemia.

Kumar L, Kumari M, Menon H.

Natl Med J India. 2002 Sep-Oct;15(5):298. No abstract available. Erratum in: Natl Med J India. 2002 Nov-Dec;15(6):350..

PMID:
12502149
13.

Concomitant myelodysplastic syndrome and chronic myeloid leukaemia: treatment outcomes with imatinib mesylate.

Mesa RA, Steensma DP, Hoyer J, Ketterling RP.

Br J Haematol. 2003 Oct;123(2):366-7. No abstract available.

PMID:
14531922
14.

Double Philadelphia-chromosome: a resistance factor on the imatinib mesylate therapy for chronic myeloid leukemia.

Otero L, Ornellas MH, Dobbin J, de Souza Fernandez T.

Int J Lab Hematol. 2008 Aug;30(4):346-8. doi: 10.1111/j.1751-553X.2007.00957.x. No abstract available.

PMID:
18665834
15.

Factors predicting molecular and cytogenetic response in chronic myeloid leukemia patients treated with imatinib.

Roche-Lestienne C, Darré S, Laï JL, Facon T, Guilhot J, Preudhomme C.

Haematologica. 2005 Jan;90(1):131-3.

16.

The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia.

Wang L, Pearson K, Ferguson JE, Clark RE.

Br J Haematol. 2003 Mar;120(6):990-9.

PMID:
12648069
17.

The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review.

Garside R, Round A, Dalziel K, Stein K, Royle P.

Health Technol Assess. 2002;6(33):1-162. Review. No abstract available.

18.

Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia.

Steegmann JL, Moreno G, Aláez C, Osorio S, Granda A, de la Cámara R, Arranz E, Reino FG, Salvanés FR, Fernández-Rañada JM, Muñoz C.

Haematologica. 2003 Jul;88(7):762-8.

19.

Successful outcome of pregnancy in chronic myeloid leukaemia treated with imatinib.

Heartin E, Walkinshaw S, Clark RE.

Leuk Lymphoma. 2004 Jun;45(6):1307-8. No abstract available.

PMID:
15360020
20.

Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.

Hardling M, Wei Y, Palmqvist L, Swolin B, Stockelberg D, Gustavsson B, Ekeland-Sjöberg K, Wadenvik H, Ricksten A.

Med Oncol. 2004;21(4):349-58.

PMID:
15579919
Items per page

Supplemental Content

Write to the Help Desk